DNLI
Price
$17.97
Change
-$0.81 (-4.31%)
Updated
Jan 16, 04:59 PM (EDT)
Capitalization
2.93B
45 days until earnings call
Intraday BUY SELL Signals
ELVN
Price
$26.67
Change
+$1.50 (+5.96%)
Updated
Jan 16, 04:59 PM (EDT)
Capitalization
1.49B
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs ELVN

Header iconDNLI vs ELVN Comparison
Open Charts DNLI vs ELVNBanner chart's image
Denali Therapeutics
Price$17.97
Change-$0.81 (-4.31%)
Volume$26.25K
Capitalization2.93B
Enliven Therapeutics
Price$26.67
Change+$1.50 (+5.96%)
Volume$31.66K
Capitalization1.49B
DNLI vs ELVN Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
ELVN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. ELVN commentary
Jan 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and ELVN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 17, 2026
Stock price -- (DNLI: $18.78 vs. ELVN: $25.17)
Brand notoriety: DNLI and ELVN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 120% vs. ELVN: 122%
Market capitalization -- DNLI: $2.93B vs. ELVN: $1.49B
DNLI [@Biotechnology] is valued at $2.93B. ELVN’s [@Biotechnology] market capitalization is $1.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileELVN’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • ELVN’s FA Score: 1 green, 4 red.
According to our system of comparison, ELVN is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while ELVN’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • ELVN’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, both DNLI and ELVN are a bad buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а +10.02% price change this week, while ELVN (@Biotechnology) price change was +8.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.08%. For the same industry, the average monthly price growth was +4.20%, and the average quarterly price growth was +43.03%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

ELVN is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (-0.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.93B) has a higher market cap than ELVN($1.49B). ELVN YTD gains are higher at: 63.442 vs. DNLI (13.749). ELVN has higher annual earnings (EBITDA): -111.97M vs. DNLI (-534.17M). DNLI has more cash in the bank: 848M vs. ELVN (478M). ELVN has less debt than DNLI: ELVN (387K) vs DNLI (44.4M). DNLI (0) and ELVN (0) have equivalent revenues.
DNLIELVNDNLI / ELVN
Capitalization2.93B1.49B196%
EBITDA-534.17M-111.97M477%
Gain YTD13.74963.44222%
P/E RatioN/AN/A-
Revenue00-
Total Cash848M478M177%
Total Debt44.4M387K11,473%
FUNDAMENTALS RATINGS
DNLI vs ELVN: Fundamental Ratings
DNLI
ELVN
OUTLOOK RATING
1..100
1429
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
4738
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ELVN's Valuation (25) in the null industry is significantly better than the same rating for DNLI (93) in the Biotechnology industry. This means that ELVN’s stock grew significantly faster than DNLI’s over the last 12 months.

ELVN's Profit vs Risk Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that ELVN’s stock grew similarly to DNLI’s over the last 12 months.

ELVN's SMR Rating (96) in the null industry is in the same range as DNLI (97) in the Biotechnology industry. This means that ELVN’s stock grew similarly to DNLI’s over the last 12 months.

ELVN's Price Growth Rating (38) in the null industry is in the same range as DNLI (47) in the Biotechnology industry. This means that ELVN’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as ELVN (100) in the null industry. This means that DNLI’s stock grew similarly to ELVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIELVN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
82%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
ELVN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMCFX11.750.19
+1.64%
Royce Micro-Cap Svc
JGRCX112.680.69
+0.62%
Janus Henderson Enterprise C
ARFFX18.790.10
+0.54%
Ariel Focus Investor
SIDRX14.070.05
+0.36%
Hartford Schroders Intl Multi-Cp Val SDR
CCCAX6.23-0.01
-0.16%
Center Coast Brookfield Midstream Foc A

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+2.79%
BEAM - DNLI
53%
Loosely correlated
-9.49%
RGNX - DNLI
52%
Loosely correlated
-7.96%
VIR - DNLI
52%
Loosely correlated
-9.09%
SYRE - DNLI
52%
Loosely correlated
-0.21%
VCYT - DNLI
50%
Loosely correlated
-3.42%
More

ELVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with MLTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVN
1D Price
Change %
ELVN100%
-3.38%
MLTX - ELVN
44%
Loosely correlated
-6.09%
TERN - ELVN
42%
Loosely correlated
-0.54%
DNLI - ELVN
42%
Loosely correlated
+2.79%
ZNTL - ELVN
42%
Loosely correlated
-9.97%
WVE - ELVN
41%
Loosely correlated
-3.03%
More